Pentoxifylline for the treatment of negative symptoms of Schizophrenia
Phase 2
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20090117001556N143
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Diagnosis of schizophrenia based on DSM-5
Age between 18-60
At least 2 years have been passed since the diagnosis
Have been stable with risperidone treatment for at least 2 months
<14 HDRS score
>15 PANSS score for negative symptoms
Exclusion Criteria
Head trauma
History of shock therapy during the last three months
Neurosurgery
Diagnosis of acute or chronic systemic disease
History of drug allergy to risperidone or pentoxifylline
Alcohol or drug addiction in the last 6 months
Suicidal ideation
Pregnancy or lactation
IQ less than 70 based on the diagnosis of a psychiatrist.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method